Bio-Rad Q1 Revenues Up 2 Percent; Will Pay Up to $110M for GnuBio | GenomeWeb

NEW YORK (GenomeWeb) — Bio-Rad said after the close of the market on Tuesday that its first quarter revenues increased 2 percent as its Life Science sales spiked 3 percent year over year.

The company also disclosed that its acquisition of sequencing technology developer GnuBio, announced earlier this year, is worth up to $110 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.